Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in the third quarter of 2026, up about 21% from a year earlier and consisting of over 358,000 total oncology tests. The Irving, Texas, company reported the numbers on Nov. 4 alongside revenue of $275.4 million, up 27% from $216.8 million a year earlier. It also raised its full-year revenue outlook to $1.04 billion to $1.05 billion, which works out to 28% to 29% growth over 2025.

The case count is the familiar part. The product list is newer. In the same release, distributed through PR Newswire, Caris said it has launched Caris Assure Therapy Response Monitoring. The new test takes the company's blood-based Caris Assure platform past the choice of a therapy and into repeated tracking of how a patient responds to treatment. Caris is targeting a launch before year-end for Caris Confirm, a whole-genome, tumor-informed test for minimal residual disease. For practices, that suggests Caris tests could show up at visits after a therapy is chosen, not only when it is being selected.

Investors focused on a different page of the release. Caris shares fell 21.49% on Nov. 5, according to KoalaGains' daily top-movers analysis, which said surging operating expenses and negative quarterly free cash flow overshadowed the revenue growth. The two readings describe one strategy from opposite ends. By the company's own account, part of the spending investors punished is tied to launching the newer tests that practices will be asked to order.

Four tests along one patient's course

Halbert, Caris's founder, chairman and CEO, called it "another record quarter" in the release. He said each case comes with molecular depth, from whole exome and whole transcriptome to whole genome or AI-driven digital pathology. That depth, he said, "is what allows us to move across the entire cancer journey." The products named in the third-quarter release:

1. Caris Detect, introduced to a consumer audience through two national advertising campaigns featuring Kevin Costner and Jordan Spieth that spotlight the importance of early-stage cancer detection.
2. Caris Assure for therapy selection, enhanced with therapy-focused sequencing depth reaching 40,000x and RNA reads increased to about 600 million.
3. Caris Assure Therapy Response Monitoring, which extends the same blood-based platform to serial checks on how treatment is working.
4. Caris Confirm, a whole-genome, tumor-informed minimal residual disease assay, targeted to launch before year-end.

The middle two items matter most for practice workflow. Therapy selection is usually a single order made around a treatment decision. Serial monitoring, by definition, means repeat blood draws on the same patient. The depth upgrade is a technical detail with a practical point behind it. Sequencing depth counts how many times each stretch of DNA gets read, and in a blood sample, where tumor DNA makes up only a small share of what's circulating, more reads give the test more chances to catch it.

For practices that already send tissue or blood to Caris for therapy selection, the monitoring product means the same lab could receive several orders per patient over a course of care. For groups weighing residual-disease testing, Confirm's launch adds one more candidate to that evaluation. The Detect campaigns work at the other end of the sequence, aimed at consumers rather than ordering physicians.

Paying for the build

Operating expenses reached $163.0 million in the quarter, up $48.1 million, or 42%, from $114.9 million a year earlier. Caris tied the increase mainly to headcount, research and development, and marketing. Operating activities used $22.2 million in cash, against $62.4 million generated in the same quarter of 2025, and the company listed commercial expansion, marketing, R&D and an inventory build-up for new solution launches among the reasons.

That inventory item is the most direct link between the cash line and the product list. Stock built ahead of launches is money spent before the related tests generate orders. That fits a quarter in which one Assure product had just launched and Confirm was still on the way.

The headcount line has a visible shape, too. Per KoalaGains, which drew on Seeking Alpha's coverage of the guidance, Caris expanded its active sales territories from 82 to 146 and grew its direct sales force to 325 professionals to support the new product rollouts. Management also raised its full-year 2026 operating expense projection to approximately $620 million. For oncology practices, 64 additional territories suggests more offices could hear from a Caris representative as the monitoring and residual-disease products roll out.

On the revenue side, molecular profiling services did nearly all the work. That line brought in $262.7 million of the quarter's total, up 27% from $207.6 million, which Caris attributed to higher clinical case volume and improvements in average selling price. Gross profit rose to $182.3 million from $147.5 million even as the margin slipped, a decline KoalaGains attributed to higher input costs and ramp-up fees for new lab equipment.

Caris posted net income of $15.3 million, or $0.05 per diluted share against $0.08 a year earlier, and reaffirmed its outlook of roughly 20% growth in clinical therapy selection volume. That suggests the new tests are being added to a growing base rather than replacing it. The company also has about $72.1 million left under a share repurchase program of up to $100.0 million.

That distinction is useful for a lab director checking whether a vendor can keep up with demand. A profiling partner that stays net-profitable while funding launches is in a different position from one that has to choose between the two. For practices adding a new test to their ordering, how stable the vendor is matters about as much as the test's specifications.

Why investors sold a record quarter

Revenue wasn't the problem. KoalaGains put the consensus analyst estimate about $20 million below what Caris delivered, and noted that net income fell 37% year over year. In its explanation, the selling came down to margins and timing. The stock was already trading near its 52-week high at a premium valuation, so any deterioration in profit margins set off swift liquidations.

The contrast with August helps explain it. Caris's second-quarter revenue of $263.7 million also beat projections, and the stock jumped more than 15% in a single day, per KoalaGains. Third-quarter revenue came in about $11.7 million higher than that. When a bigger top line draws the opposite reaction, the cost side of the report is the likelier explanation, and that is where KoalaGains puts it.

Its argument rests on how Caris earns money. The company bills commercial health insurers, Medicare and regional healthcare systems for its testing, and running the labs takes sequencing machines, expensive reagents and specialized pathology staff. In KoalaGains' view, if overhead grows faster than reimbursement revenue, strong sales won't turn into dependable free cash flow.

That is a fair test of the reading that this spending builds a multi-stage testing business. The build would pay off only if the monitoring and residual-disease tests bring in reimbursed volume that covers the territories and reps added to sell them. Investors and practices end up watching the same thing: whether ordering patterns actually change.

1.2 million profiles and a pancreatic signature

Through Sept. 30, Caris had passed 1.2 million total profiles and 845,000 matched profiles, including more than 849,000 whole transcriptome profiles and 796,000 whole exome profiles. In its Oct. 15 announcement of the earnings date, the company described its clinico-genomic database and computing capability as a platform for building diagnostic solutions covering early detection, diagnosis, monitoring, therapy selection and drug development.

Caris also published a validation of its Caris AI Insights pancreatic cancer signature, showing that a molecular signature built on AI can predict benefit from first-line treatment.

This is where the monitoring and residual-disease products could matter beyond their own revenue. A therapy selection test captures a patient at one moment. Repeat draws during treatment could add data points over time on the same patient, the kind of record a signature like the pancreatic one depends on. That's an inference from how the products are designed, not a result Caris has reported.

If it held, it would have a commercial side as well as a clinical one. KoalaGains notes that Caris licenses data and research tools from its clinico-genomic database to pharmaceutical companies to speed up drug discovery. A deeper record per patient would therefore feed a second revenue stream in addition to the testing bill.

What arrives before year-end

The next dated milestone is Caris Confirm, which the company has targeted for launch before the end of 2026. Full-year results will then show whether the raised $1.04 billion to $1.05 billion range holds. The clearer test of this reading comes after that: whether monitoring and residual-disease orders start appearing as their own volume figure, separate from the therapy selection growth Caris guides to today.

If those numbers show up and grow, the cost increase will look like the setup cost of a multi-stage testing business. If therapy selection keeps doing nearly all the work, the spending will need another explanation. Either way, the practices placing the orders will be the first to see it.